The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called GLP-1.

Our study also identified other risks, including low blood pressure, sleep problems, headaches, formation of kidney stones, ...

Canada ranks last among G7 nations when it comes to access to new medications. For example, a treatment for cholangiocarcinoma — a rare form of cancer that forms in a patient's bile ducts ...

But many people who take daily medications are unaware that certain drugs in their pill box can also increase their risk of falling, which can lead to devastating, even fatal, complications. Falls are ...

Bile duct cancer, or cholangiocarcinoma ... of seven key medicines to drive the disease back. Some people on the drugs have seen their cancer go into remission, while others have had previously ...

Bile duct cancer (also called cholangiocarcinoma ... patients that a lot can be done for this type of cancer. While the drugs may extend lives, some of them have been shown in preliminary work ...

Bile duct cancer (also called cholangiocarcinoma or biliary ... study will show medics and patients that a lot can be done for this type of cancer. While the drugs may extend lives, some of them have ...

While the drugs may extend lives ... Around 5,000 to 6,000 people every year are diagnosed with bile duct cancer but medics suspect the true figure is higher. The number of deaths each year ...

Before the advent of medications, individuals with these more extreme symptoms often found themselves stuck—unable to engage meaningfully in therapy or, in many cases, requiring long-term ...

It is unlikely, therefore, that any company will develop a drug to treat the condition, which is why Omary and his colleagues tested existing medications. The research team screened more than ...

"The $7.3 billion is the difference between what they are reimbursing themselves and what it is estimated to cost them to acquire the drug," an FTC spokesperson told reporters in a press briefing ...